Inhibitory effects of retinoic acid on invasiveness of human thyroid carcinoma cell lines in vitro

Journal of Endocrinological Investigation

Volumn 32, Issue 9, 2009, Pages 731-738

  Lan, L ^a   Cui, D ^b   Luo, Y ^c   Shi, B Y ^d   Deng, L L ^a   Zhang, G Y ^a   Wang, H ^a  

^a Jishuitan Orthopaedic College of Tsinghua University   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

C643; HTH74; Invasion; Retinoic acid; Thyroid carcinoma

Indexed keywords

GELATINASE A; PLASMINOGEN ACTIVATOR; RETINOIC ACID; UROKINASE; UROKINASE RECEPTOR; UVOMORULIN;

ADULT; ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL ADHESION; CELL DIFFERENTIATION; CELL INVASION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; METASTASIS INHIBITION; PROTEIN EXPRESSION; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADULT; CADHERINS; CELL ADHESION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; THYROID NEOPLASMS; TRETINOIN; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 74949103948     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/bf03346528     Document Type: Article

References (46)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998, 83: 2638-48.
2. Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996, 37: 598-605.
3. Frohlich E, Machicao F, Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer 2005, 12: 291-303.
4. Elisei R, Vivaldi A, Agate L, et al. All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes. J Clin Endocrinol Metab 2005, 90: 2403-11.
5. Liu YY, Stokkel MP, Pereira AM, et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol 2006, 154: 525-31.
6. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. Modulation of human renal cell carcinoma 786-0 MMP-2 and MMP-9 activity by inhibitors and inducers in vitro. Med Oncol 2006, 23: 245-50.
7. Joshi S, Guleria R, Pan J, DiPette D, Singh US. Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 2006, 25: 240-7.
8. Papi A, Bartolini G, Ammar K, et al. Inhibitory effects of retinoic acid and HF on growth, migration and invasiveness in the U87MG human glioblastoma cell line. Oncol Rep 2007, 18: 1015-21.
9. Hendrix MJ, Wood WR, Seftor EA, et al. Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor. Cancer Res 1990, 50: 4121-30.
10. Pereda MP, Hopfner U, Pagotto U, et al. Retinoic acid stimulates meningioma cell adhesion to the extracellular matrix and inhibits invasion. Br J Cancer 1999, 81: 381-6.
11. Wu XZ, Zhang L, Shi BZ, Hu P. Inhibitory effects of N-(4-hydrophenyl) retinamide on liver cancer and malignant melanoma cells. World J Gastroenterol 2005, 11: 5763-9.
12. Goretzki PE, Frilling A, Simon D, Roeher HD. Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res 1990, 118: 48-63.
13. Heldin NE, Gustavsson B, Claesson-Welsh L, et al. Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line. Proc Natl Acad Sci U S A 1988, 85: 9302-6.
14. Heldin NE, Cvejic D, Smeds S, Westermark B. Coexpression of functionally active receptors for thyrotropin and platelet-derived growth factor in human thyroid carcinoma cells. Endocrinology 1991, 129: 2187-93.
15. Zielke A, Tezelman S, Jossart GH, et al. Establishment of a highly differentiated thyroid cancer cell line of Hurthle cell origin. Thyroid 1998, 8: 475-83.
16. Schmutzler C, Brtko J, Winzer R, et al. Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues. Int J Cancer 1998, 76: 368-76.
17. Luo Y, He DL, Ning L, et al. Over-expression of hypoxia-inducible factor-1 alpha increases the invasive potency of LNCaP cells in vitro. BJU Int 2006, 98: 1315-9.
18. Palecek SP, Loftus JC, Ginsberg MH, Lauffenburger DA, Horwitz AF. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature 1997, 385: 537-40.
19. Liotta LA. Tumor invasion and metastases - Role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res 1986, 46: 1-7.
20. Price JT, Bonovich MT, Kohn EC. The biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol 1997, 32: 175-253.
21. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001, 23: 912-23.
22. Boyer B, Valles AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 2000, 60: 1091-9.
23. Naito A, Iwase H, Kuzushima T, Nakamura T, Kobayashi S. Clinical significance of E-cadherin expression in thyroid neoplasms. J Surg Oncol 2001, 76: 176-80.
24. McCaffrey JC. Aerodigestive tract invasion by well-differentiated thyroid carcinoma: diagnosis, management, prognosis, and biology. Laryngoscope 2006, 116: 1-11.
25. Mondino A, Resnati M, Blasi F. Structure and function of the urokinase receptor. Thromb Haemost 1999, 82: 19-22.
26. Costantini V, Sidoni A, Deveglia R, et al. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer 1996, 77: 1079-88.
27. Xing RH, Rabbani SA. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int J Cancer 1996, 67: 423-9.
28. Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P. Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 2004, 49: 179-86.
29. Kim SJ, Shiba E, Taguchi T, et al. uPA receptor expression in benign and malignant thyroid tumors. Anticancer Res 2002, 22: 387-93.
30. Chu QD, Hurd TC, Harvey S, et al. Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis. Diagn Mol Pathol 2004, 13: 241-6.
31. Ito Y, Takeda T, Kobayashi T, et al. Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study. Anticancer Res 1996, 16: 81-9.
32. Cho Mar K, Eimoto T, Tateyama H, Arai Y, Fujiyoshi Y, Hamaguchi M. Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology 2006, 48: 286-94.
33. Simon D, Koehrle J, Reiners C, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998, 22: 569-74.
34. Schreck R, Schnieders F, Schmutzler C, Kohrle J. Retinoids stimulate type I iodothyronine 5′-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 1994, 79: 791-8.
35. Schmutzler C, Kohrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000, 10: 393-406.
36. Coelho SM, Corbo R, Buescu A, Carvalho DP, Vaisman M. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest 2004, 27: 334-9.
37. Zhang Y., Jia S., Liu Y., et al. A clinical study of all-trans-retinoid- induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun 2007, 28: 251-5.
38. Kim WG, Kim EY, Kim TY, et al. Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. Endocr J 2009, 56: 105-12.
39. Gruning T, Tiepolt C, Zophel K, et al. Retinoic acid for redifferentiation of thyroid cancer - Does it hold its promise? Eur J Endocrinol 2003, 148: 395-402.
40. Courbon F, Zerdoud S, Bastie D, et al. Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma. Thyroid 2006, 16: 1025-31.
41. Paez Pereda M, Missale C, Grubler Y, et al. Nerve growth factor and retinoic acid inhibit proliferation and invasion in thyroid tumor cells. Mol Cell Endocrinol 2000, 167: 99-106.
42. Simon D, Korber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 2002, 29: 775-82.
43. Matarrese P, Giandomenico V, Fiorucci G, et al. Antiproliferative activity of interferon alpha and retinoic acid in SiHa carcinoma cells: the role of cell adhesion. Int J Cancer 1998, 76: 531-40.
44. Nakagawa K, Sogo S, Hioki K, Tokunaga R, Taketani S. Acquisition of cell adhesion and induction of focal adhesion kinase of human colon cancer Colo 201 cells by retinoic acid-induced differentiation. Differentiation 1998, 62: 249-57.
45. Schmutzler C, Hoang-Vu C, Ruger B, Kohrle J. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. Eur J Endocrinol 2004, 150: 547-56.
46. Haugen BR, Larson LL, Pugazhenthi U, et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 2004, 89: 272-80.